- CND Life Sciences, Inc., a Phoenix, AZ-based innovative medical technology company, closed a $2.4m seed financing round
- HonorHealth, a local health system serving 1.6 million people in the greater Phoenix area, joined several experienced financial investors in funding the round
- The company also intends to use the funds to expand laboratory operations and accelerate sales and marketing initiatives for its Syn-One TestTM
- CND Life Sciences is pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers
- The Syn-One Test is a breakthrough in diagnosing a group of neurodegenerative diseases called synucleinopathies
- Since launching in late 2019, the Syn-One Test has ordered by more than 100 neurologists in 20 states to help diagnose patients early in the disease process as possible
